Stay updated with breaking news from Global Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DGAP-News: Formycon AG / Key word(s): Study results/Study Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficac...
DGAP-News: Formycon AG / Key word(s): Study results/StudyFormycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara®* in Phase III Study 16.08.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release // August 16, 202...
16.08.2022 - DGAP-News: Formycon AG / Key word(s): Study results/Study Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara* in Phase III Study 16.08.2022 / 07:30 CET/CEST The issuer is solely responsible ... Seite 1
Press release content from Business Wire. The AP news staff was not involved in its creation.
Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met its co-primary endpoints in a planned interim analysis at 35 weeks. In the trial, eplontersen reached a ...